

• HHS Reference No. E-128-2006—PCT Application No. PCT/US2007/071412.

Licensing Contact: Charlene Sydnor, Ph.D.; 301-435-4689; sydnorc@mail.nih.gov.

Collaborative Research Opportunity: The National Institute on Drug Abuse is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Potent and Selective Analogues of Modafinil and Uses Thereof. For collaboration opportunities, please contact Michelle Kim Leff, MD, MBA at mleff@mail.nih.gov.

Translocator Protein 18 kDa PET Radioligands With High Affinities Regardless of Genotype

Description of Technology: This technology relates to a group of Translocator protein 18 kDa (TSPO) radioligands for Positron Emission Tomography (PET) that are specific and accurate, regardless of genotype. TSPO is a mitochondrial protein expressed in inflammatory cells, which is a marker for neuroinflammation. Neuroinflammation is symptomatic of many neuropsychiatric and neurodegenerative disorders, such as multiple sclerosis, stroke, epilepsy, dementia, and traumatic brain injuries. Monitoring and quantifying TSPO 18 kDa with radioligands in PET may have clinical application in understanding, diagnosing and treating many neuropsychiatric disorders. However, current TSPO 18 kDa radioligands either lack specificity or, due to TSPO polymorphisms, have highly variable inter-subject sensitivities depending on genotype. These new ligands are specific and accurate, regardless of genotype, allowing simplified interpretation and quantification of the binding signal.

Potential Commercial Applications: Biomarker or diagnostic for neuroinflammation

Competitive Advantages: Specific and accurate, regardless of genotype

Development Stage:

- Early-stage
- Pre-clinical
- In vivo data available (animal)

Inventors: Robert B. Innis, Victor W. Pike, Sam S. Zoghbi, Yi Zhang (NIMH); Sabrina Castellano (University of Salerno, Italy); Giorgio Stefancich (University of Trieste, Italy); Sabrina Talia, Federico Da Settimo, Claudia Martini (University of Pisa, Italy)

Publications:

1. Oh U, *et al.* Translocator protein PET imaging for glial activation in multiple sclerosis. *J Neuroimmune*

Pharmacol. 2011 Sep;6(3):354–61.

[PMID 20872081]

2. Kreisl WC, *et al.* Stroke incidentally identified using improved positron emission tomography for microglial activation. *Arch Neurol.* 2009 Oct;66(1):1288–9. [PMID 19822787]

3. Hirvonen J, *et al.* Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. *J Nucl Med.* 2012 Feb;53(2):234–40. [PMID 22238156]

4. Kreisl WC, *et al.* In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. *Brain.* 2013 Jul;136(Pt 7):2228–38. [PMID 23775979]

Intellectual Property: HHS Reference No. E-262-2012/0—U.S. Provisional Patent Application No. 61/777, 542 filed March 12, 2013

Licensing Contact: Edward (Tedd) Fenn, J.D.; 424-500-2005; Tedd.fenn@nih.gov.

Collaborative Research Opportunity: The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize TSPO radioligands for monitoring inflammation. For collaboration opportunities, please contact Suzanne Winfield at winfiels@mail.nih.gov.

Dated: July 25, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013-18329 Filed 7-30-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

Date: August 26, 2013.

Time: 11:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Betty Poon, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, (301) 402-6891, poonb@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: July 25, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-18327 Filed 7-30-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the teleconference meeting of the National Cancer Institute Board of Scientific Advisors *ad hoc* Subcommittee on HIV/AIDS Malignancy, August 08, 2013, 10:30 a.m. to 12:00 p.m., National Cancer Institute, NIH, Building 10, Room 10S255, 10 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on July 24, 2013, 78FR44577.

This meeting notice is amended to provide a change in location for the public. The location for the public is National Cancer Institute Shady Grove, 9609 Medical Center Drive, Seventh Floor, West Tower, Room 7W034, Rockville, MD 20850. As previously indicated, members of the public may also dial-in to the teleconference using the following number: 866-492-1791. The meeting is open to the public.

Dated: July 25, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-18326 Filed 7-30-13; 8:45 am]

BILLING CODE 4140-01-P